Utah Medical Products, Inc. (UTMD) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↓
9.00
-3% vs avg
5yr avg: 9.31
30Y Low5.1·High14.7
P/FCF
↓
15.00
-3% vs avg
5yr avg: 15.46
30Y Low3.9·High24.4
P/B Ratio
↓
1.82
↓-26% vs avg
5yr avg: 2.47
30Y Low1.5·High6.4
ROE
↓
9.5%
↑-25% vs avg
5yr avg: 12.7%
30Y Low10%·High79%
Debt/EBITDA
↑
0.02
+2% vs avg
5yr avg: 0.02
30Y Low0.0·High1.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
UTMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Utah Medical Products, Inc. trades at 19.3x earnings, roughly in line with its 5-year average of 19.4x, sitting at the 77th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 13%. On a free-cash-flow basis, the stock trades at 15.0x P/FCF, roughly in line with the 5-year average of 15.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $215M | $181M | $215M | $306M | $366M | $366M | $310M | $403M | $311M | $304M | $274M |
| Enterprise Value | $129M | $96M | $133M | $214M | $292M | $305M | $258M | $361M | $260M | $264M | $248M |
| P/E Ratio → | 19.26 | 16.08 | 15.52 | 18.43 | 22.24 | 24.75 | 28.67 | 27.39 | 16.78 | 35.70 | 22.59 |
| P/S Ratio | 5.58 | 4.71 | 5.26 | 6.10 | 7.01 | 7.46 | 7.34 | 8.60 | 7.41 | 7.35 | 6.97 |
| P/B Ratio | 1.82 | 1.52 | 1.83 | 2.39 | 3.21 | 3.42 | 3.01 | 3.99 | 3.50 | 3.89 | 3.96 |
| P/FCF | 15.00 | 12.66 | 14.75 | 14.15 | 18.02 | 17.72 | 16.06 | — | 18.95 | 19.87 | 24.41 |
| P/OCF | 14.62 | 12.34 | 14.52 | 13.75 | 17.32 | 17.26 | 15.37 | 23.65 | 18.50 | 17.99 | 18.86 |
P/E links to full P/E history page with 30-year chart
UTMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Utah Medical Products, Inc.'s enterprise value stands at 9.0x EBITDA, roughly in line with its 5-year average of 9.3x. The Healthcare sector median is 14.2x, placing the stock at a 37% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.49 | 3.24 | 4.26 | 5.58 | 6.23 | 6.12 | 7.70 | 6.20 | 6.38 | 6.30 |
| EV / EBITDA | 9.00 | 6.67 | 8.10 | 9.23 | 10.85 | 11.67 | 12.35 | 14.73 | 12.02 | 12.13 | 13.02 |
| EV / EBIT | 11.34 | 6.79 | 9.76 | 11.59 | 14.73 | 16.18 | 18.84 | 20.48 | 13.92 | 13.90 | 15.30 |
| EV / FCF | — | 6.69 | 9.09 | 9.88 | 14.34 | 14.79 | 13.40 | — | 15.84 | 17.26 | 22.06 |
UTMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
Utah Medical Products, Inc. earns an operating margin of 29.6%. Operating margins have compressed from 33.4% to 29.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 9.5% is modest. ROIC of 25.0% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.6% | 51.6% | 59.0% | 59.8% | 61.6% | 63.0% | 60.6% | 62.8% | 62.6% | 63.7% | 60.3% |
| Operating Margin | 29.6% | 29.6% | 33.2% | 33.4% | 37.9% | 38.5% | 32.5% | 37.6% | 44.5% | 45.9% | 41.2% |
| Net Profit Margin | 29.3% | 29.3% | 33.9% | 33.1% | 31.5% | 30.1% | 25.6% | 31.4% | 44.2% | 20.5% | 30.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.5% | 9.5% | 11.3% | 13.7% | 14.9% | 14.1% | 10.6% | 15.5% | 22.2% | 11.5% | 17.5% |
| ROA | 9.2% | 9.2% | 10.8% | 12.8% | 13.8% | 13.0% | 9.7% | 14.1% | 19.3% | 10.0% | 15.6% |
| ROIC | 25.0% | 25.0% | 28.9% | 33.4% | 34.5% | 28.9% | 18.7% | 27.4% | 36.8% | 35.1% | 27.2% |
| ROCE | 9.6% | 9.6% | 10.9% | 13.5% | 17.2% | 17.2% | 12.8% | 17.6% | 20.5% | 23.6% | 21.8% |
UTMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Utah Medical Products, Inc. carries a Debt/EBITDA ratio of 0.0x, which is very conservative (100% below the sector average of 3.2x). The company holds a net cash position — cash of $86M exceeds total debt of $225000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | — | — | — |
| Net Debt / Equity | — | -0.72 | -0.70 | -0.72 | -0.65 | -0.57 | -0.50 | -0.42 | -0.57 | -0.51 | -0.38 |
| Net Debt / EBITDA | -5.96 | -5.96 | -5.05 | -4.00 | -2.78 | -2.32 | -2.45 | -1.73 | -2.36 | -1.83 | -1.39 |
| Debt / FCF | — | -5.97 | -5.67 | -4.28 | -3.68 | -2.93 | -2.66 | — | -3.11 | -2.60 | -2.35 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($86M) exceeds total debt ($225000)
UTMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Utah Medical Products, Inc.'s current ratio of 37.62x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 34.57x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 22.56x to 37.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 37.62 | 37.62 | 25.64 | 22.56 | 15.09 | 19.53 | 16.42 | 15.92 | 11.58 | 9.32 | 11.54 |
| Quick Ratio | 34.57 | 34.57 | 23.29 | 20.53 | 13.61 | 17.77 | 14.78 | 13.91 | 10.55 | 8.32 | 10.03 |
| Cash Ratio | 33.01 | 33.01 | 22.09 | 19.72 | 12.59 | 16.28 | 13.61 | 12.41 | 9.72 | 7.57 | 8.72 |
| Asset Turnover | — | 0.31 | 0.33 | 0.37 | 0.42 | 0.42 | 0.38 | 0.43 | 0.42 | 0.45 | 0.51 |
| Inventory Turnover | 2.35 | 2.35 | 1.90 | 2.11 | 2.28 | 2.75 | 2.67 | 2.52 | 2.90 | 2.86 | 3.44 |
| Days Sales Outstanding | — | 33.37 | 36.53 | 24.64 | 38.66 | 38.18 | 35.52 | 36.90 | 34.38 | 31.93 | 29.82 |
UTMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Utah Medical Products, Inc. returns 5.7% to shareholders annually — split between a 1.8% dividend yield and 3.9% buyback yield. The payout ratio of 35.3% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 5.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.8% | 2.2% | 2.0% | 1.4% | 0.9% | 3.1% | 1.3% | 1.0% | 1.3% | 1.0% | 1.4% |
| Payout Ratio | 35.3% | 35.3% | 30.7% | 25.7% | 19.2% | 77.5% | 38.1% | 27.9% | 21.7% | 34.7% | 32.3% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.2% | 6.2% | 6.4% | 5.4% | 4.5% | 4.0% | 3.5% | 3.7% | 6.0% | 2.8% | 4.4% |
| FCF Yield | 6.7% | 7.9% | 6.8% | 7.1% | 5.6% | 5.6% | 6.2% | — | 5.3% | 5.0% | 4.1% |
| Buyback Yield | 3.9% | 4.6% | 9.3% | 0.0% | 0.7% | 0.0% | 2.3% | 0.1% | 0.4% | 0.9% | 1.0% |
| Total Shareholder Yield | 5.7% | 6.8% | 11.3% | 1.4% | 1.5% | 3.1% | 3.6% | 1.1% | 1.7% | 1.9% | 2.5% |
| Shares Outstanding | — | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M |
Peer Comparison
Compare UTMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 UTMDYou | $215M | 19.3 | 9.0 | 15.0 | 51.6% | 29.6% | 9.5% | 25.0% | 0.0 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 MMSI | $4B | 31.6 | 14.0 | 18.6 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 LMAT | $2B | 37.3 | 29.3 | 28.7 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 ANGO | $505M | -14.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 TNDM | $1B | -5.0 | — | — | 52.3% | -7.7% | -97.9% | -10.0% | — |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 INMD | $849M | 9.4 | 6.5 | 10.1 | 78.5% | 23.0% | 13.5% | 13.5% | 0.2 |
 COO | $13B | 35.2 | 14.0 | 29.6 | 60.7% | 16.7% | 4.6% | 4.8% | 2.5 |
 BDX | $52B | 24.7 | 14.0 | 19.5 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
UTMD — Frequently Asked Questions
Quick answers to the most common questions about buying UTMD stock.
What is Utah Medical Products, Inc.'s P/E ratio?
Utah Medical Products, Inc.'s current P/E ratio is 19.3x. The historical average is 16.8x. This places it at the 77th percentile of its historical range.
What is Utah Medical Products, Inc.'s EV/EBITDA?
Utah Medical Products, Inc.'s current EV/EBITDA is 9.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.7x.
What is Utah Medical Products, Inc.'s ROE?
Utah Medical Products, Inc.'s return on equity (ROE) is 9.5%. The historical average is 22.5%.
Is UTMD stock overvalued?
Based on historical data, Utah Medical Products, Inc. is trading at a P/E of 19.3x. This is at the 77th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Utah Medical Products, Inc.'s dividend yield?
Utah Medical Products, Inc.'s current dividend yield is 1.83% with a payout ratio of 35.3%.
What are Utah Medical Products, Inc.'s profit margins?
Utah Medical Products, Inc. has 51.6% gross margin and 29.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Utah Medical Products, Inc. have?
Utah Medical Products, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.